Hans Peter Gröchenig1, Thomas Waldhör2, Thomas Haas3, Heimo Wenzl4, Pius Steiner5, Robert Koch6, Thomas Feichtenschlager7, Gerald Eckhardt8, Andreas Mayer9, Andreas Kirchgatterer10, Othmar Ludwiczek11, Reingard Platzer12, Pavol Papay13, Johanna Gartner14, Harry Fuchssteiner15, Wolfgang Miehsler16, Paul-Gerhard Peters17, Gerhard Reicht18, Maximilian Kutschera19, Clemens Dejaco19, Harald Vogelsang19, Gottfried Novacek19. 1. Department of Internal Medicine, Hospital Brothers of St. John of God St. Veit an der Glan, St. Veit an der Glan. 2. Department of Epidemiology, Center of Public Health, Medical University of Vienna, Vienna. 3. Darmpraxis Salzburg, Salzburg. 4. Department of Internal Medicine, Division of Gastroenterology and Hepatology, Medical University of Graz, Graz. 5. Department of Internal Medicine I, Hospital Wels-Grieskirchen, Wels. 6. Department of Internal Medicine I, Medical University of Innsbruck, Innsbruck. 7. Department of Internal Medicine IV, Hospital Rudolfstiftung, Vienna. 8. Department of Internal Medicine, Hospital Oberpullendorf, Oberpullendorf. 9. Department of Internal Medicine II, Universitätsklinikum St. Pölten, St. Pölten. 10. Department of Internal Medicine V, Hospital Wels-Grieskirchen, Grieskirchen. 11. Department of Internal Medicine, Hospital Hall in Tirol, Hall in Tirol. 12. Department of Internal Medicine I, Hospital Wiener Neustadt, Wiener Neustadt. 13. Department of Internal Medicine, Franziskus Hospital. 14. Department of Internal Medicine, Hanusch Hospital, Vienna. 15. Hospital Elisabethinen Linz, Department of Internal Medicine IV, Linz. 16. Department of Internal Medicine, Hospital Brothers of St. John of God Salzburg, Salzburg. 17. Department of Internal Medicine, Hospital Feldkirch, Feldkirch. 18. Department of Internal Medicine II, Hospital Brothers of St. John of God Graz, Graz, Austria. 19. Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.
Abstract
OBJECTIVE: Complementary and alternative medicine (CAM) seems to be frequently used among patients with inflammatory bowel disease (IBD). We aimed to determine the prevalence and indicators of CAM use in Austrian IBD patients. METHODS: In a multicentre cross-sectional study, adult patients with IBD attending 18 Austrian outpatient clinics completed a multi-item questionnaire that recorded use of CAM as well as medical and socioeconomic characteristics. Patients were recruited between June 2014 and June 2015. The study outcome was the prevalence of CAM use and its socioeconomic and disease-related associations. RESULTS: A total of 1286 patients (Crohn's disease 830, ulcerative colitis 435, IBD unclassified 21; females 651) with a median age of 40 years (interquartile range 31-52 years) and a median disease duration of 10 years (4-18 years) were analysed. The prevalence of previous and/or current CAM use was 50.7%, with similar results for Crohn's disease and ulcerative colitis. In the multivariable analysis, female gender and a university education were independent socioeconomic indicators of CAM use. IBD-related indicators were longer duration of the disease and previous and/or current treatment with steroids and TNF-α inhibitors. CONCLUSION: CAM use for IBD is frequent in Austrian IBD patients and associated with female gender, higher educational level of university degree, longer duration of the disease, and treatment with steroids and TNF-α inhibitors.
OBJECTIVE: Complementary and alternative medicine (CAM) seems to be frequently used among patients with inflammatory bowel disease (IBD). We aimed to determine the prevalence and indicators of CAM use in Austrian IBD patients. METHODS: In a multicentre cross-sectional study, adult patients with IBD attending 18 Austrian outpatient clinics completed a multi-item questionnaire that recorded use of CAM as well as medical and socioeconomic characteristics. Patients were recruited between June 2014 and June 2015. The study outcome was the prevalence of CAM use and its socioeconomic and disease-related associations. RESULTS: A total of 1286 patients (Crohn's disease 830, ulcerative colitis 435, IBD unclassified 21; females 651) with a median age of 40 years (interquartile range 31-52 years) and a median disease duration of 10 years (4-18 years) were analysed. The prevalence of previous and/or current CAM use was 50.7%, with similar results for Crohn's disease and ulcerative colitis. In the multivariable analysis, female gender and a university education were independent socioeconomic indicators of CAM use. IBD-related indicators were longer duration of the disease and previous and/or current treatment with steroids and TNF-α inhibitors. CONCLUSION: CAM use for IBD is frequent in Austrian IBD patients and associated with female gender, higher educational level of university degree, longer duration of the disease, and treatment with steroids and TNF-α inhibitors.
Authors: Maximilian Kutschera; Thomas Waldhör; Gottfried Novacek; Wolfgang Miehsler; Hans Peter Gröchenig; Thomas Haas; Heimo Wenzl; Pius Steiner; Robert Koch; Thomas Feichtenschlager; Gerald Eckhardt; Andreas Mayer; Andreas Kirchgatterer; Othmar Ludwiczek; Reingard Platzer; Pavol Papay; Johanna Gartner; Harry Fuchssteiner; Paul-Gerhard Peters; Gerhard Reicht; Gabriele Moser; Clemens Dejaco; Harald Vogelsang; Christian Primas Journal: United European Gastroenterol J Date: 2021-02-18 Impact factor: 4.623